Beta Bionics, Inc. (NASDAQ:BBNX) Given Average Rating of “Moderate Buy” by Analysts

Beta Bionics, Inc. (NASDAQ:BBNX) has received an average recommendation of “Moderate Buy” from the twelve analysts that are covering the firm, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $23.44.

Several research analysts have recently commented on BBNX shares. Wolfe Research started coverage on Beta Bionics in a research report on Friday, May 30th. They issued an “outperform” rating and a $20.00 target price for the company. Lake Street Capital started coverage on Beta Bionics in a research report on Thursday, June 12th. They issued a “buy” rating and a $30.00 target price for the company. The Goldman Sachs Group started coverage on Beta Bionics in a research report on Friday, May 30th. They issued a “neutral” rating and a $16.00 target price for the company. Finally, Truist Financial started coverage on Beta Bionics in a research report on Monday, June 16th. They issued a “buy” rating and a $26.00 target price for the company.

Insider Buying and Selling

In related news, CFO Stephen Feider sold 1,497 shares of the firm’s stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $17.89, for a total value of $26,781.33. Following the sale, the chief financial officer now directly owns 45,503 shares in the company, valued at $814,048.67. This trade represents a 3.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders have sold 4,519 shares of company stock valued at $80,845.

Institutional Trading of Beta Bionics

Large investors have recently added to or reduced their stakes in the business. Strs Ohio acquired a new stake in Beta Bionics in the 1st quarter valued at approximately $29,000. Corebridge Financial Inc. acquired a new stake in Beta Bionics in the 1st quarter valued at approximately $79,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Beta Bionics in the 1st quarter valued at approximately $95,000. MetLife Investment Management LLC acquired a new stake in Beta Bionics in the 1st quarter valued at approximately $102,000. Finally, Deutsche Bank AG acquired a new position in shares of Beta Bionics during the 1st quarter valued at $148,000.

Beta Bionics Stock Up 0.5%

Shares of BBNX opened at $15.07 on Friday. Beta Bionics has a one year low of $8.89 and a one year high of $24.50. The company has a 50-day simple moving average of $15.09.

Beta Bionics (NASDAQ:BBNX) last issued its earnings results on Tuesday, May 6th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.01).

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.